Literature DB >> 24589695

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.

Daniel J Rader1, John J P Kastelein.   

Abstract

Entities:  

Keywords:  anticholesteremic agents; cholesterol; hyperlipoproteinemia type 2; lipoproteins, LDL

Mesh：

Substances：

Year:  2014        PMID： 24589695     DOI： 10.1161/CIRCULATIONAHA.113.001292

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  69 in total

Review 1.  The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors:  Anandita Agarwala; Peter Jones; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

2.  Stepping toward therapeutic CRISPR.

Authors:  Keith T Gagnon; David R Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

Review 3.  Familial hypercholesterolemia.

Authors:  Victoria Enchia Bouhairie; Anne Carol Goldberg
Journal:  Cardiol Clin       Date:  2015-05       Impact factor: 2.213

4.  Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish.

Authors:  Chao Liu; Young Sook Kim; Jungsu Kim; Jennifer Pattison; Andrés Kamaid; Yury I Miller
Journal:  J Lipid Res       Date:  2017-11-29       Impact factor: 5.922

5.  AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.

Authors:  Suryanarayan Somanathan; Frank Jacobs; Qiang Wang; Alexandra L Hanlon; James M Wilson; Daniel J Rader
Journal:  Circ Res       Date:  2014-07-14       Impact factor: 17.367

6.  Lomitapide.

Authors:  Sebastiaan C Goulooze; Adam F Cohen; Robert Rissmann
Journal:  Br J Clin Pharmacol       Date:  2015-07-02       Impact factor: 4.335

Review 7.  Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.

Authors:  Bhavin B Adhyaru; Terry A Jacobson
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

Review 8.  Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.

Authors:  Evan A Stein; Frederick J Raal
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

Review 9.  Novel Therapies for Familial Hypercholesterolemia.

Authors:  Justin Parizo; Ashish Sarraju; Joshua W Knowles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11

Review 10.  Non-coding RNAs as drug targets.

Authors:  Masayuki Matsui; David R Corey
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.